New Findings on Statin-Related Muscle Pain

About 10 percent of individuals taking statins for cholesterol reduction report experiencing unexplained muscle discomfort. This issue often leads many to stop using these critical medications.

Researchers from Columbia University and the University of Rochester have determined that statin-associated muscle symptoms (SAMS)—which encompass pain and fatigue—are linked to an unsettling rise in calcium within the muscle cells. This excess calcium can cause tissue damage and even lead to severe health issues.

Statins function by inhibiting an enzyme necessary for cholesterol production in the liver. Consequently, levels of ‘bad’ LDL cholesterol are lowered in the bloodstream, which helps stave off major cardiovascular diseases, including atherosclerosis—the accumulation of fatty plaque within blood vessels.

However, statins also influence ‘off-target’ proteins such as the ryanodine receptor 1 (RyR1). This particular protein acts as a gateway located in the sarcoplasmic reticulum surrounding muscle fibers.

Think of RyR1 like a club bouncer—it regulates calcium ion flow into the muscles, which is critical for muscle contraction.

In their studies, researchers looked at how statins interact with RyR1 through an imaging technique known as cryo-electron microscopy. This method involves freezing biological samples very quickly and then examining them with electron beams. The patterns created by bouncing electrons allow for detailed 3D representations of structures like proteins.

It appears that cholesterol-lowering drugs such as simvastatin may inadvertently keep these gates open, resulting in calcium leaking into muscle cells. This leakage can either harm the muscles directly or activate enzymes that lead to further muscle degradation.

This situation can lead to ongoing pain, muscle weakness, tenderness, and even cramping. Those with RyR1 mutations might face heightened issues, including episodes of malignant hyperthermia, which causes severe overheating due to medications, or diaphragm weakness that can affect lung function.

In rare instances, statin side effects can lead to rhabdomyolysis, a serious condition where muscle tissue tears and leaks into the bloodstream, potentially causing kidney failure.

There’s also a rare chance of developing autoimmune-mediated necrotizing myositis, where the immune system mistakenly attacks healthy muscle tissue.

While the calcium gate theory may not explain all cases of SAMS, understanding this mechanism could help pinpoint individuals at higher risk for statin intolerance. Approximately 40 million adults in the U.S. use statins, and around 10 percent of those experience SAMS.

Lead author Andrew Marks, a cardiologist at Columbia University, noted, “I’ve seen patients refuse statins because of side effects. It’s the most common reason patients stop taking them, and it’s a significant issue that needs addressing.”

To address these concerns, researchers propose two promising strategies. One involves redesigning statins so they don’t bind to RyR1 while still effectively lowering cholesterol. Another approach was successful in treating statin-intolerant mice with Rycal, a novel drug that managed to close the leaky RyR1 gates and mitigate muscle weakness caused by simvastatin.

This study is detailed in the Journal of Clinical Investigation.